UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
09/940,986	08/29/2001	Thomas V. Ressemann	891,144-010	6847	
	7590 03/22/2007 & MYERS LLP	EXAMINER			
610 NEWPORT	CENTER DRIVE		STIGELL, THEODORE J		
17TH FLOOR NEWPORT BE	EACH, CA 92660		ART UNIT	PAPER NUMBER	
	,		3763		
SHORTENED STATUTOR	Y PERIOD OF RESPONSE	MAIL DATE	DELIVER	DELIVERY MODE	
3 MONTHS		03/22/2007	PAPER		

Please find below and/or attached an Office communication concerning this application or proceeding.

If NO period for reply is specified above, the maximum statutory period will apply and will expire 6 MONTHS from the mailing date of this communication.

		\7				
	Application No.	Applicant(s)				
	09/940,986	RESSEMANN ET AL.				
Office Action Summary	Examiner	Art Unit				
	Theodore J. Stigell	3763				
The MAILING DATE of this communication app Period for Reply	pears on the cover sheet with the	e correspondence address				
A SHORTENED STATUTORY PERIOD FOR REPL' WHICHEVER IS LONGER, FROM THE MAILING D. - Extensions of time may be available under the provisions of 37 CFR 1.1 after SIX (6) MONTHS from the mailing date of this communication. - If NO period for reply is specified above, the maximum statutory period or Failure to reply within the set or extended period for reply will, by statute Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b).	ATE OF THIS COMMUNICATION 36(a). In no event, however, may a reply be will apply and will expire SIX (6) MONTHS from the application to become ABANDO	ON. timely filed om the mailing date of this communication. NED (35 U.S.C. § 133).				
Status						
1) Responsive to communication(s) filed on 16 F	ebruary 2007.					
2a) This action is FINAL . 2b) ⊠ This	This action is FINAL . 2b)⊠ This action is non-final.					
3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is						
closed in accordance with the practice under E	Ex parte Quayle, 1935 C.D. 11,	453 O.G. 213.				
Disposition of Claims						
4)⊠ Claim(s) <u>1-19</u> is/are pending in the application		•				
4a) Of the above claim(s) is/are withdrawn from consideration.						
5) Claim(s) is/are allowed.						
6)⊠ Claim(s) <u>1-19</u> is/are rejected.						
7) Claim(s) is/are objected to.		•				
8) Claim(s) are subject to restriction and/o	or election requirement.					
Application Papers						
9) The specification is objected to by the Examine	er.					
10) The drawing(s) filed on is/are: a) acc	epted or b) objected to by the	e Examiner.				
Applicant may not request that any objection to the	drawing(s) be held in abeyance.	See 37 CFR 1.85(a).				
Replacement drawing sheet(s) including the correct	tion is required if the drawing(s) is	objected to. See 37 CFR 1.121(d).				
11) ☐ The oath or declaration is objected to by the Ex	xaminer. Note the attached Office	ce Action or form PTO-152.				
Priority under 35 U.S.C. § 119						
12) Acknowledgment is made of a claim for foreign	priority under 35 U.S.C. § 119	(a)-(d) or (f).				
a) ☐ All b) ☐ Some * c) ☐ None of:						
1. Certified copies of the priority documents have been received.						
2. Certified copies of the priority documents have been received in Application No						
3. Copies of the certified copies of the prio		ived in this National Stage				
application from the International Bureau	, , , ,					
* See the attached detailed Office action for a list	of the certified copies not recei	ived.				
Attachment(s)	_					
Notice of References Cited (PTO-892) Notice of Draftsperson's Patent Drawing Review (PTO-948)	4) Interview Summa Paper No(s)/Mail					
3) 🔀 Information Disclosure Statement(s) (PTO/SB/08) 5) 🔲 Notice of Informal Patent Application						
Paper No(s)/Mail Date	6) Other:					

Application/Control Number: 09/940,986

Art Unit: 3763

DETAILED ACTION

Response to Amendment

Claim Rejections - 35 USC § 102

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless -

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

Claims 1-19 are rejected under 35 U.S.C. 102(b) as being anticipated by Zadno-Azizi et al. (6,022,336). See column 22, lines 1-46. Zadno-Azizi discloses a method of treatment of a blood vessel comprising advancing an evacuation sheath assembly (410) into the blood vessel, stopping normal antegrade blood flow in the blood vessel proximate the stenosis, advancing a therapeutic catheter (420) into the blood vessel, treating the stenosis with the therapeutic catheter and removing the therapeutic catheter (see column 22, lines 5-10), advancing an infusion catheter (not shown) to a location distal to the stenosis after removing the therapeutic catheter, infusing the blood vessel with a fluid supplied by the infusion catheter, and inducing retrograde flow within the blood vessel to carry the infused fluid and embolic material dislodged during treating into the evacuation sheath assembly, wherein advancing the infusion catheter includes advancing the infusion catheter through a distal end of the evacuation sheath assembly, wherein stopping blood flow includes creating a first seal (412) between the evacuation sheath and the blood vessel and creating a second seal between a guide catheter and a proximal portion of the evacuation sheath assembly, wherein the retrograde flow

Application/Control Number: 09/940,986

Art Unit: 3763

includes applying a vacuum through the evacuation sheath, treating the stenosis includes advancing an angioplasty balloon (426), wherein treating the stenosis includes advancing a stent to the stenosis, and wherein inducing retrograde flow involves venting pressure as is well- known in the art, wherein the blood vessel can be a coronary artery or saphenous vein graft, wherein the step of stopping normal antegrade blood flow is performed prior to advancing the device across the stenosis, wherein infusing the blood vessel in done through infusion port, and wherein saline, blood, or radiopaque dye can be infuse into the blood vessel, wherein the evacuation sheath is advanced through guide catheter and further applying a vacuum to the guide catheter and further comprising inducing retrograde flow prior to advancing the infusion catheter to move debris proximal to the treated stenosis.

Response to Arguments

Applicant's arguments with respect to claims 1-19 have been considered but are moot in view of the new ground(s) of rejection.

Conclusion

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Theodore J. Stigell whose telephone number is 571-272-8759. The examiner can normally be reached on M-F 8:30-5:00.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Nicholas Lucchesi can be reached on 571-272-4977. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Application/Control Number: 09/940,986

Art Unit: 3763

Page 4

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.